4/A: Camp4 Therapeutics: Polaris Management Amends Form 4 Filing to Include Brian Chee

Polaris Management Co. VII, L.L.C. amends its Form 4 filing to include Brian Chee as an additional reporting person after the automatic conversion of preferred stock to common stock following Camp4 Therapeutics' IPO.

Summary

• This is an amendment to a Form 4 filing related to Camp4 Therapeutics Corp (CAMP).
• The amendment, filed on October 22, 2024, updates the original Form 4 from October 15, 2024.
• The purpose of the amendment is to add Brian Chee as an additional reporting person.
• The filing details transactions related to the conversion of Series A Prime Convertible Preferred Stock and Series B Preferred Stock into common stock upon the closing of Camp4 Therapeutics' initial public offering (IPO) on October 15, 2024.
• Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Amy Schulman and Brian Chee are listed as reporting persons.
• The transactions involve the acquisition and disposition of common stock due to the conversion of preferred stock.
• Brian Chee was not initially included as a reporting person in the original filing due to a lack of EDGAR system codes at the time.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, especially after events like an IPO.

Stakeholder Impact

• The conversion of preferred stock to common stock impacts shareholders by increasing the number of outstanding shares.

Key Dates